title: Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
abstract: OBJECTIVE
  To report on the safety and clinical use of combined subconjunctival and intracorneal bevacizumab for corneal neovascularization.
  
  
  METHODS
  The charts of 12 consecutive patients with corneal neovascularization who received combined subconjunctival and intracorneal injections of bevacizumab (2.5 mg/0.1 mL) were reviewed. Patients received 1 to 3 injections of 2.5 mg of bevacizumab (1.25 mg/0.05 mL subconjunctival and 1.25 mg/0.05 mL intrastromal). Morphological changes were assessed clinically by 1 investigator.
  
  
  RESULTS
  Combined subconjunctival and intracorneal injections of bevacizumab were effective and well-tolerated. No significant ocular or systemic adverse events were observed during 6.4 months (range, 0.25-22 months) of follow-up. All patients showed a reduction in the neovascularized area.
  
  
  CONCLUSIONS
  Short-term results suggest that combined subconjunctival and intracorneal injections of bevacizumab are an effective method for reducing corneal neovascularization. It may be a useful option or adjunct to other treatments in stabilizing or improving vision.
authors.affiliation: Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. sonia.y@gmail.com
authors.forename: Sonia N
authors.initials: SN
authors.lastname: Yeung
authors.forename: Alejandro
authors.initials: A
authors.lastname: Lichtinger
authors.forename: Peter
authors.initials: P
authors.lastname: Kim
authors.forename: Maoz D
authors.initials: MD
authors.lastname: Amiran
authors.forename: Allan R
authors.initials: AR
authors.lastname: Slomovic
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D003228:Conjunctiva / Q000187:drug effects; D003315:Cornea / Q000187:drug effects; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D056965:Injections, Intraocular; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab